Custom-Made brain cancer vaccine shows promise in early trial
NCT ID NCT02287428
First seen Mar 14, 2026 · Last updated Jun 21, 2026 · Updated 13 times
Summary
This early-phase trial tests a personalized vaccine (NeoVax) made from each patient's unique tumor mutations, combined with radiation and the immunotherapy drug pembrolizumab (Keytruda), in people with newly diagnosed glioblastoma. The main goals are to see if the vaccine can be made safely and to check for side effects. About 56 participants are enrolled across several groups, some also receiving standard chemotherapy. The study is not yet recruiting and is actively following patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02113, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Personalized neoantigen vaccine (NeoVax) plus pembrolizumab (Keytruda) and radiation therapy
What this could lead to
If successful, this could point toward a new treatment approach that uses a patient's own tumor mutations to train the immune system to fight glioblastoma, potentially delaying recurrence.
What could go wrong
This is an early phase 1 trial with only 56 participants, focused on safety and feasibility. The vaccine is personalized and complex to produce, and it is not yet proven to work. Adding immunotherapy may increase side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.